UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 10-KSB/A
(AMENDMENT NO. 1)
-------------
(Mark One)
[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2004.
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ________ TO ________.
COMMISSION FILE NUMBER: 0-16159
LECTEC CORPORATION
(Name of small business issuer in its charter)
MINNESOTA 41-1301878
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
5616 LINCOLN DRIVE, EDINA, MINNESOTA 55436
(Address of principal executive offices) (Zip Code)
Issuer's telephone number, including area code: (952) 933-2291
Securities registered under Section 12(b) of the Exchange Act: NONE
Securities registered under Section 12(g) of the Exchange Act: COMMON STOCK, PAR VALUE $0.01 PER SHARE
(Title of class)
Indicate by check mark whether the issuer (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-B is not contained in this form; and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [ ]
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act) Yes [ ] No [X]
The Issuer's revenues for the fiscal year ended December 31, 2004 were
$1,065,000.
The aggregate market value of the voting and non-voting common equity held
by non-affiliates of the registrant as of April 13, 2005 was approximately
$10,174,845 based upon the last reported sale price of the Common Stock at that
date by the Over-the-Counter Bulletin Board.
The number of shares outstanding of the Issuer's Common Stock as of April
14, 2005 was 4,152,998 shares.
-----------------------------------
DOCUMENTS INCORPORATED BY REFERENCE
NONE
Transitional Small Business Disclosure Format (Check One): Yes [ ] No [X]
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-KSB/A ("Form 10-KSB/A") to the Annual Report on
Form 10-KSB of LecTec Corporation ("LecTec") for the fiscal year ended December
31, 2004, initially filed with the Securities and Exchange Commission (the
"SEC") on April 15, 2005 (the "Original Filing"), is being filed solely to amend
Item 7 of Part II to change the date of the report of Grant Thornton LLP,
LecTec's former independent registered public accounting firm, contained
therein. In accordance with SEC rules, Item 7 of Part II is being re-filed in
this Form 10-KSB/A in its entirety. In addition, pursuant to the rules of the
SEC, Item 13 of Part III of the Original Filing has been amended to contain (1)
a revised, currently-dated consent from LecTec's current independent registered
public accounting firm, (2) a revised, currently-dated consent from LecTec's
former independent registered public accounting firm, and (3) currently-dated
certifications from LecTec's principal executive officer and principal financial
officer as required by Section 302 and 906 of the Sarbanes-Oxley Act of 2002.
Such consents and certifications are attached to this Form 10-KSB/A as Exhibits
23.01, 23.02, 31.01, 31.02 and 32.01.
No other information in the Original Filing is amended hereby. Except for the
foregoing amended information, this Form 10-KSB/A continues to describe
conditions as of the date of the Original Filing, and LecTec has not updated the
disclosures contained herein to reflect events that occurred at a later date.
PART II
ITEM 7. FINANCIAL STATEMENTS
The balance sheet of the Company as of December 31, 2004, and the related
statements of operations, shareholders' equity (deficit), and cash flows for the
year then ended and the notes thereto have been audited by Lurie Besikof Lapidus
& Company, LLP, Independent Registered Public Accounting Firm.
The balance sheet of the Company as of December 31, 2003, and the related
statements of operations, shareholders' equity (deficit), and cash flows for the
year then ended and the notes thereto have been audited by Grant Thornton LLP,
Independent Registered Public Accounting Firm.
CONTENTS
Page
----
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.................. 3
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.................. 4
FINANCIAL STATEMENTS
BALANCE SHEETS........................................................ 5
STATEMENTS OF OPERATIONS.............................................. 7
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT).......................... 8
STATEMENTS OF CASH FLOWS.............................................. 9
NOTES TO FINANCIAL STATEMENTS......................................... 11
2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and
Board of Directors
LecTec Corporation
We have audited the accompanying balance sheet of LecTec
Corporation, as of December 31, 2004, and the related statements of operations,
shareholders' equity (deficit), and cash flows for the year then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audit included consideration of
internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we express no such opinion. An audit also
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe our audit provides a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above
present fairly, in all material respects, the financial position of LecTec
Corporation as of December 31, 2004, and the results of its operations and its
cash flows for the year then ended in conformity with accounting principles
generally accepted in the United States of America.
/s/ LURIE BESIKOF LAPIDUS & COMPANY, LLP
Minneapolis, Minnesota
March 6, 2005
3
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Shareholders and
Board of Directors
LecTec Corporation
We have audited the accompanying balance sheet of LecTec
Corporation as of December 31, 2003, and the related statements of operations,
shareholders' equity (deficit), and cash flows for the year then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audit included consideration of
internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we express no such opinion. An audit also
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.
In our opinion the financial statements referred to above
present fairly, in all material respects, the financial position of LecTec
Corporation as of December 31, 2003, and the results of its operations and its
cash flows for the year then ended in conformity with accounting principles
generally accepted in the United States of America.
/s/ GRANT THORNTON, LLP
Minneapolis, Minnesota
April 14, 2005
4
LECTEC CORPORATION
BALANCE SHEETS
DECEMBER 31, 2004 AND 2003
ASSETS 2004 2003
---------- ----------
(Restated)
CURRENT ASSETS:
Cash and cash equivalents $2,239,318 $ 483,844
Prepaid expenses and other 137,981 63,653
Discontinued operations 192,629 1,931,558
---------- ----------
Total current assets 2,569,928 2,479,055
OTHER ASSETS:
Patents and trademarks 50,693 211,595
Prepaid insurance - director and officer 182,513 --
---------- ----------
233,206 211,595
---------- ----------
$2,803,134 $2,690,650
========== ==========
The accompanying notes are an integral part of these financial statements.
5
LECTEC CORPORATION
BALANCE SHEETS - CONTINUED
DECEMBER 31, 2004 AND 2003
LIABILITIES AND
SHAREHOLDERS' EQUITY (DEFICIT) 2004 2003
------------ ------------
(Restated)
CURRENT LIABILITIES:
Current maturities of long-term obligations $ 2,525 $ 12,564
Accounts payable 4,944 19,801
Accrued expenses 240,293 140,107
Discontinued operations 273,290 2,609,508
------------ ------------
Total current liabilities 521,052 2,781,980
------------ ------------
LONG-TERM OBLIGATIONS, less current maturities -- 62,438
COMMITMENTS AND CONTINGENCIES -- --
SHAREHOLDERS' EQUITY (DEFICIT):
Common stock, $.01 par value; 15,000,000 shares
authorized; 4,030,330 and 3,979,327 shares issued
and outstanding at December 31, 2004 and 2003 40,303 39,793
Additional contributed capital 11,689,404 11,550,743
Accumulated deficit (9,447,625) (11,744,304)
------------ ------------
2,282,082 (153,768)
------------ ------------
$ 2,803,134 $ 2,690,650
============ ============
The accompanying notes are an integral part of these financial statements.
6
LECTEC CORPORATION
STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2004 AND 2003
2004 2003
----------- -----------
(Restated)
CONTINUING OPERATIONS:
Revenue - royalty and licensing fee income $ 1,065,000 $ --
Operating expenses 1,189,601 1,615,430
----------- -----------
Loss from continuing operations
before income taxes (124,601) (1,615,430)
Income tax benefit 1,448 --
----------- -----------
Loss from continuing operations (123,153) (1,615,430)
----------- -----------
DISCONTINUED OPERATIONS:
Earnings from discontinued operations
before income taxes 2,448,280 333,669
Income tax expense (28,448) --
----------- -----------
Earnings from discontinued operations 2,419,832 333,669
----------- -----------
Net earnings (loss) $ 2,296,679 $(1,281,761)
=========== ===========
Weighted average common shares outstanding:
Basic and diluted 4,011,631 3,967,529
Earnings (loss) per share:
Basic and diluted -
Continuing operations $ (0.03) $ (0.40)
Discontinued operations 0.60 0.08
----------- -----------
Total $ 0.57 $ (0.32)
=========== ===========
The accompanying notes are an integral part of these financial statements.
7
LECTEC CORPORATION
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
YEARS ENDED DECEMBER 31, 2004 AND 2003
Common stock Additional
--------------------------- contributed Accumulated
Shares Amount capital deficit Total
------------ ------------ ------------ ------------ ------------
Balance at January 1, 2003 3,966,395 $ 39,664 $ 11,389,678 $(10,462,543) $ 966,799
Common shares issued in connection with the
employee stock purchase plan 12,932 129 3,065 -- 3,194
Warrants issued in connection with the sale
of building -- -- 158,000 -- 158,000
Net loss -- -- -- (1,281,761) (1,281,761)
------------ ------------ ------------ ------------ ------------
Balance at December 31, 2003 3,979,327 39,793 11,550,743 (11,744,304) (153,768)
Stock compensation expense -- -- 112,640 -- 112,640
Exercise of stock options 51,003 510 26,021 -- 26,531
Net earnings -- -- -- 2,296,679 2,296,679
------------ ------------ ------------ ------------ ------------
Balance at December 31, 2004 4,030,330 $ 40,303 $ 11,689,404 $ (9,447,625) $ 2,282,082
============ ============ ============ ============ ============
The accompanying notes are an integral part of these financial statements.
8
LECTEC CORPORATION
STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2004 AND 2003
2004 2003
----------- -----------
(Restated)
Cash flows from operating activities:
Loss from continuing operations $ (123,153) $(1,615,430)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Earnings from discontinued operations 2,419,832 333,669
Loss on impaired assets 115,055 19,437
Depreciation and amortization 212,284 523,267
(Gain) loss on sale of property, plant and equipment (611,954) 52,375
Compensation expense related to re-priced stock options 112,640 --
Changes in continuing operations assets and liabilities:
Prepaid expenses and other (256,842) --
Accounts payable (14,857) --
Accrued expenses 100,186 --
Change in net assets and liabilities of discontinued operations (1,074,352) 659,382
----------- -----------
Net cash provided by (used in) operating activities 878,839 (27,300)
Cash flows from investing activities:
Purchases of property, plant and equipment (74,550) (22,001)
Proceeds from sales of property, plant and equipment 968,700 845,000
Investment in patents and trademarks (31,473) (49,905)
----------- -----------
Net cash provided by investing activities 862,677 773,094
Cash flows from financing activities:
Proceeds from the issuance of common stock 26,531 3,194
Repayment of mortgage note payable -- (820,000)
Repayment of long-term obligations (12,573) (116,732)
----------- -----------
Net cash provided by (used in) financing activities 13,958 (933,538)
----------- -----------
Net increase (decrease) in cash and cash equivalents 1,755,474 (187,744)
Cash and cash equivalents - beginning of year 483,844 671,588
----------- -----------
Cash and cash equivalents - end of year $ 2,239,318 $ 483,844
=========== ===========
The accompanying notes are an integral part of these financial statements.
9
LECTEC CORPORATION
STATEMENTS OF CASH FLOWS - CONTINUED
YEARS ENDED DECEMBER 31, 2004 AND 2003
2004 2003
-------- --------
Supplemental disclosures of cash flow information:
Cash paid for interest $ 10,395 $ 26,009
Cash paid for income taxes $ -- $ 3,000
Supplemental disclosures of noncash activities:
Licensing fees used to reduce long-term obligations and
accrued interest $250,000 --
Leasehold improvement in exchange for lease obligation $ -- $ 66,560
Fair value of warrants issued with the sale of building $ -- $158,000
Value of free rent received with the sale of building $ -- $228,512
The accompanying notes are an integral part of these financial statements.
10
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
LecTec Corporation (the "Company") is currently an intellectual property
licensing and holding company. The Company receives royalties and licensing
fees from licensing agreements pertaining to the Company's patents. The
Company currently has one licensing agreement with Novartis Consumer Health,
Inc. ("Novartis"), which will pay the Company royalties on a semi-annual
basis based upon a percentage of Novartis net sales as specified in the
Agreement. Previously, the Company was a contract manufacturer of hydrogel
topical patches sold to major pharmaceutical customers until the Company
ceased its manufacturing operations in December 2004. A summary of the
Company's significant accounting policies consistently applied in the
preparation of the accompanying financial statements follows:
Use of Estimates
In preparing financial statements in conformity with accounting principles
generally accepted in the United States of America, management is required to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.
Cash and Cash Equivalents
The Company considers all highly liquid temporary investments purchased with
original maturities of three months or less to be cash equivalents.
Accounts Receivable (discontinued operations Note C)
The Company grants credit to customers in the normal course of business, but
generally does not require collateral or other security to support amounts
due. Management performs on-going credit evaluation of customers when deemed
necessary.
Accounts receivable are generally due within 30 days and are stated at
amounts due from customers net of an allowance for doubtful accounts.
Accounts receivable outstanding longer than the contractual payment terms are
considered past due. The Company determines its allowance by considering a
number of factors, including the length of time trade accounts receivable are
past due, the Company's previous loss history, the customer's ability to pay
its obligation to the Company, and the condition of the general economy and
the industry as a whole. The Company writes off accounts receivable against
the allowance when they become uncollectible, and payments subsequently
received on such receivables are credited to the allowance for doubtful
accounts. At December 31, 2004, the Company had one receivable with Novartis
of $176,207. This receivable was paid during the first quarter of 2005.
Inventories (discontinued operations Note C)
Inventories were stated at the lower of cost (determined on a first-in,
first-out basis) or market and consist of the following:
DECEMBER 31,
-----------------------
2004 2003
---------- ----------
Raw materials $ -- $ 465,050
Work in process -- 41,354
Finished goods -- 587,065
---------- ----------
$ -- $1,093,469
========== ==========
11
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
Long-Lived Assets
Property, plant, and equipment is recorded at cost. Depreciation is provided
in amounts sufficient to relate the cost of depreciable assets to operations
over their estimated service lives. The straight-line method of depreciation
is followed for financial reporting purposes, and accelerated methods are
used for tax purposes. Estimated useful lives used in the calculation of
depreciation are:
Leasehold improvements Life of lease
Equipment 4 - 15 years
Furniture and fixtures 5 - 7 years
Patents and trademarks consist primarily of the cost of applying for patents
and trademarks and are amortized on a straight-line basis over the estimated
useful life of the asset, generally five years.
Amortized intangible assets consist of the following:
DECEMBER 31, 2004 DECEMBER 31, 2003
----------------------------- -----------------------------
GROSS CARRYING ACCUMULATED GROSS CARRYING ACCUMULATED
AMOUNT AMORTIZATION AMOUNT AMORTIZATION
-------------- ------------ -------------- ------------
Patents $ 231,922 $ 181,229 $1,508,613 $1,298,900
Trademarks -- -- 8,162 6,280
---------- ---------- ---------- ----------
$ 231,922 $ 181,229 $1,516,775 $1,305,180
========== ========== ========== ==========
Amortization expense of amortized intangible assets totaled $77,320 and
$104,734 for 2004 and 2003. Amortization expense is expected to be as
follows:
YEAR ENDING DECEMBER 31,
------------------------
2005 $ 19,092
2006 13,471
2007 10,273
2008 6,808
2009 1,049
The carrying value of long-lived assets is reviewed periodically or when
factors indicating impairment are present. The impairment loss is measured as
the amount by which the carrying value of the assets exceeds the fair value
of the assets. Based on the Company's decision to wind down manufacturing
operations, the Company reviewed its long-lived assets for impairment during
the third quarter of 2004. The Company recorded a charge of $115,055 for
impaired patents and wrote off fully amortized patents of $1,201,271 at
September 30, 2004. The Company believes that no impairment exists at
December 31, 2004.
Revenue Recognition
Royalty and licensing income is recognized when earned under the terms of the
agreements with customers and collection is reasonably assured. Domestic
sales revenue was recognized when the product was shipped to the customer and
collection was probable. International sales revenue was recognized when the
product was received by the customer and collection was probable.
12
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
Research and Development (discontinued operations)
Research and development costs are expenses as incurred.
Income Taxes
Income taxes are accounted for under the liability method. Deferred income
taxes are provided for temporary differences between the financial reporting
and tax basis of assets and liabilities. Deferred taxes are reduced by a
valuation allowance when, in the opinion of management, it is more likely
than not that some portion or all of the deferred tax asset will not be
realized. Deferred tax assets and liabilities are adjusted for the effects of
changes in tax laws and rates on the date of the enactment.
Net Earnings (Loss) Per Share
Basic net earnings (loss) per share is computed by dividing net earnings
(loss) by the weighted average number of common shares outstanding. Diluted
net earnings (loss) per share is computed by dividing net earnings (loss) by
the weighted average number of common shares outstanding and common share
equivalents related to stock options and warrants when dilutive.
Common stock options and warrants to purchase 814,124 and 1,020,301 shares of
common stock with a weighted average exercise price of $1.96 and $2.14 were
outstanding at December 31, 2004 and 2003, respectively. As the Company had a
loss from continuing operations in both 2004 and 2003, those shares were
excluded from the net earnings (loss) per share computations because they
were anti-dilutive.
Stock Based Compensation
The Company utilizes the intrinsic value method of accounting for stock based
employee compensation plans. All options granted had an exercise price equal
to the market value of the underlying common stock on the date of grant and
no compensation cost is reflected in net loss for 2004 and 2003. The
following table illustrates the effect on net earnings (loss) if the Company
had applied the fair value recognition provisions of FASB Statement No. 123,
Accounting for Stock-Based Compensation:
Accounting for Discontinued Operations
In August 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standard ("SFAS") 144, which changed the
requirements for reporting discontinued operations as well as changed the
standards for reporting long-lived assets that have been disposed. Reporting
of discontinued operations was originally dictated under the provisions of
Accounting Principals Bulletin ("APB") 30. FASB concluded that an expansion
of those provisions was warranted, so that more disposal situations would
trigger the display of discontinued operations.
Under the provisions of SFAS 144, if a component of an entity is either
classified as held-for-sale or has been disposed of during the period, the
results of its operations are to be reported in discontinued operations,
provided that both of the following conditions are met:
o The operations and cash flows of the component have been or will be
removed from the ongoing operations of the entity as a result of the
disposal transaction, and
13
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
o The entity will have no significant continuing involvement in the
operations of the component after the disposal transaction.
The Company has exited from manufacturing operations of topical patches and
has sold off all of it's manufacturing assets related to the production of
patches to its only remaining customer, Novartis, as of December 31, 2004. The
assets related to the Company's manufacturing operations have been classified as
discontinued operations due to the sale of the manufacturing assets by December
31, 2004. The operations and cash flows of the contract manufacturing operations
will be eliminated from the ongoing operations as a result of the sales
transaction. The surviving entity (intellectual property licensing and holding
company) will not have any significant involvement in the operations of the
previously sold manufacturing operations. It is therefore managements position
that the conditions for reporting the Company's financial statements, balance
sheets and statements of cash flows under the requirements of SFAS 144 as
discontinued operations is appropriate. The comparative 2003 financial
statements have been restated to conform to the 2004 presentation.
The Company used reasonable judgment combined with quantitative analysis in
determining the amounts of assets, liabilities, revenues and expenses that would
be allocated between continuing operations and discontinued operations.
14
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
YEARS ENDED DECEMBER 31,
------------------------------
2004 2003
------------- -------------
Net earnings (loss), as reported $ 2,296,679 $ (1,281,761)
Compensation expense determined
under the fair value method (106,938) (194,706)
------------- -------------
Pro forma net earnings (loss) $ 2,189,741 $ (1,476,467)
============= =============
Net earnings (loss) per share:
As reported -
Basic and diluted
Continuing operations $ (0.03) $ (0.40)
Discontinued operations $ 0.60 0.08
------------- -------------
Total $ 0.57 $ (0.32)
============= =============
Pro forma -
Basic and diluted
Continuing operations $ (0.05) $ (0.45)
Discontinued operations $ 0.60 0.08
------------- -------------
Total $ 0.55 $ (0.37)
============= =============
15
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
The weighted average fair value of options granted during 2004 and 2003 was
$1.09 and $0.40. The fair value of each option grant is estimated on the date
of grant using the Black-Scholes option valuation model with the following
weighted-average assumptions used for all grants issued during 2004 and 2003;
zero dividend yield, expected volatility of 179% and 164%, risk-free interest
rate of 2.72% and 2.99%, and expected lives of 3.0 and 4.0 years.
The Black-Scholes option valuation model was developed for use in estimating
the fair value of traded options which have no vesting restrictions and are
fully transferable. In addition, option valuation models require the input of
several subjective assumptions. The Company's employee and director stock
options have characteristics different from those of traded options, and
changes in the subjective input assumptions can materially affect the fair
value estimate.
Fair Value of Financial Instruments
Due to their short-term nature, the carrying value of current financial
assets and liabilities approximates their fair values.
Recent Accounting Pronouncements
In January 2003, the Financial Accounting Standards Board ("FASB") issued
FASB Interpretation ("FIN") No. 46, "Consolidation of Variable Interest
Entities, an Interpretation of ARB No. 51." In December 2003, the FASB FIN
46(R), "Consolidation of Variable Interest Entities, a revision of FIN 46"
which addresses consolidation by business enterprises where equity investors
do not bear the residual economic risks and rewards. Adoption of 46(R) did
not have a material impact on the Company's financial statements.
In December 2004, the FASB issued Statements of Financial Accounting
Standards ("SFAS") No. 123(R), "Share-Based Payment," which requires that the
compensation cost relating to share- based payment transactions (including
the cost of all employee stock options) be recognized in the financial
statements. That cost will be measured based on the estimated fair value of
the equity or liability instruments issued. SFAS No. 123(R) covers a wide
range of share-based compensation arrangements including share options,
restricted share plans, performance-based awards, share appreciation rights,
and employee share purchase plans. SFAS No. 123(R) replaces SFAS No. 123,
"Accounting for Stock-Based Compensation," and supersedes Accounting
Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to
Employees." The Company is required to apply SFAS No. 123(R) in the first
interim or annual reporting period that begins after December 15, 2005. Thus,
the Company's financial statements will reflect an expense for (a) all
share-based compensation arrangements granted after December 31, 2005 and for
any such arrangements that are modified, cancelled, or repurchased after that
date, and (b) the portion of previous share-based awards for which the
requisite service has not been rendered as of that date, based on the grant
date estimated fair value. Management has not determined the future effect of
this pronouncement on its future financial statements.
The December 2004, the FASB issued SFAS No. 153, "Exchanges of Nonmonetary
Assets, an amendment of APB Opinion No. 29, Accounting for Nonmonetary
Transactions." The amendments made by SFAS No. 153 are based on the principle
that exchanges of nonmonetary assets should be measured using the estimated
fair value of the assets exchanged. SFAS No. 153 eliminates the narrow
exception for nonmonetary exchanges of similar productive assets, and
replaces it with a broader exception for exchanges of nonmonetary assets that
do not have commercial substance. A nonmonetary exchange has "commercial
substance" if the future cash flows of the entity are expected to change
significantly as a result of the transaction. This pronouncement is effective
for
16
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
nonmonetary exchanges in fiscal periods beginning after June 15, 2005. The
Company does not believe that this pronouncement will have a significant effect
on its future financial statements.
NOTE B - LICENSING AND SUPPLY AGREEMENT
On July 19, 2004, the Company entered into a supply and licensing agreement,
effective as of January 1, 2004 (the "Agreement"), with Novartis Consumer
Health, Inc. ("Novartis"). The Agreement replaced the Company's prior supply and
licensing agreement with Novartis dated May 8, 2002. The Agreement requires the
Company to manufacture, sell and deliver to Novartis vapor patches for sale to
the pediatric market in the United States, Canada and Mexico. Under the
Agreement, Novartis had the option until March 31, 2005, to extend the use of
vapor patches to the adult cough/cold category in the United States, Canada and
Mexico at no additional cost and under the same terms and conditions as set
forth in the Agreement. On March 31, 2005, Novartis notified the Company of its
intention to enter the adult market pursuant to the Agreement. In order to
provide the Company with working capital funds necessary to enable it to
manufacture and deliver vapor patches to Novartis in accordance with the
Agreement, Novartis advanced up to $2,000,000 for use by the Company to pay
current accounts payable and expenses incurred exclusively for the manufacture
and delivery of vapor patches. In consideration of any advanced funds, the
Company executed and delivered to Novartis a promissory note of $2,000,000 and a
security agreement. Under the security agreement, the Company pledged
substantially all of its assets. The note was repaid by the Company by the
delivery to Novartis of vapor patches under the Agreement. All amounts owed have
been paid as of December 31, 2004.
Under the Agreement, the Company granted Novartis an exclusive license (the
"License") to all of the intellectual property of the Company to the extent that
it is used or useful in the production of the vapor patches being supplied under
the Agreement for a fee of $1,065,000, which was paid to the Company by Novartis
as follows: (1) release of $250,000 in debt on July 19, 2004, (2) payment of
$407,500 in cash on July 22, 2004, and (3) payment of $407,500 in cash by
October 1, 2004, (the Company received this cash on September 24, 2004). The
License began on July 19, 2004, and will continue for the duration of any
patents included in the licensed intellectual property and, with respect to all
other elements of the licensed intellectual property, for the maximum duration
permitted under applicable law. Upon the expiration of the patents included in
the licensed intellectual property, Novartis will have a non-revocable,
perpetual, fully paid-up license to the intellectual property used or useful in
the production of vapor patches for the pediatric market and the adult
cough/cold market. Commencing on January 1, 2005, Novartis is required by the
Agreement to pay royalties, at an agreed upon percentage, to the Company, based
upon the net semi-annual sales of vapor patches by Novartis for each year the
License is in effect.
The supply portion of the Agreement will continue in effect until February 5,
2005, except that the provisions relating to the License will continue in effect
until the conclusion of the term of the License. The Company may not assign or
otherwise transfer the Agreement (other than to an affiliate) without the prior
written consent of Novartis, except that the Company may assign the Agreement in
connection with the transfer or sale of all or substantially all of its assets
or business or its merger or consolidation with another company, so long as (1)
such acquirer or successor in interest agrees in writing to be bound by all
conditions of the Agreement, and (2) the Company gives Novartis written notice
of any such assignment and 15 days to object. Novartis may object to an
assignment only if such acquirer or successor in interest (a) is a direct
competitor of Novartis, or (b) prior to February 5, 2005, in Novartis'
reasonable discretion, is not a manufacturer which has a proven record of
operational quality at least equal to that of the Company or does not have
sufficient financial wherewithal.
In conjunction with the signing of the Agreement, Novartis purchased certain
manufacturing equipment from the Company for approximately $900,000 in 2004. The
gain on the sale of those assets is included in discontinued operations.
17
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE C - DISCONTINUED OPERATIONS
In July 2004, management determined that the Company would be winding down its
contract manufacturing operations before December 31, 2004. Because of this, the
past and future financial results related to contract manufacturing will be
treated as discontinued operations for financial reporting purposes. Continuing
operations will consist of operations related to the surviving intellectual
property licensing and holding company. The Company accounts for its
discontinued operations under the provisions of SFAS No. 144, "Accounting for
the Impairment or Disposal of Long-Lived Assets " (SFAS 144). Accordingly,
results of operations and the related charges for discontinued operations have
been classified as "Earnings from discontinued operations" in the accompanying
Statements of Operations. Assets and liabilities of the discontinued operations
have been reclassified and reflected on the accompanying Balance Sheets as
"Discontinued operations". For comparative purposes, all prior periods presented
have been restated to reflect the reclassifications on a consistent basis.
Discontinued operations assets and liabilities and revenues include the
following:
December 31, December 31,
2004 2003
------------ ------------
DISCONTINUED OPERATIONS ASSETS
Accounts receivable, net $ 176,207 $ 203,866
Inventories -- 1,093,469
Prepaid expenses and other 16,422 157,160
Property and equipment, net -- 477,063
------------ ------------
Total discontinued operations assets $ 192,629 $ 1,931,558
============ ============
DISCONTINUED OPERATIONS LIABILITIES
Current maturities of long-term obligations $ -- $ 220,000
Accounts payable 21,267 316,948
Accrued expenses 152,023 143,446
Reserve for sales returns and credits 100,000 218,831
Customer deposits -- 1,710,283
------------ ------------
Total discontinued operations liabilities $ 273,290 $ 2,609,508
============ ============
REVENUES FOR THE YEAR ENDED $ 7,925,022 $ 7,236,935
============ ============
18
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE D - LONG-TERM OBLIGATIONS
Long-term debt consists of the following:
DECEMBER 31,
-------------------
2004 2003
-------- --------
Capital lease obligations
(continuing operations) (a) 2,525 $ 75,002
Promissory note payable
(discontinued operations) (b) -- 220,000
-------- --------
2,525 295,002
Less current maturities 2,525 232,564
-------- --------
$ -- $ 62,438
======== ========
(a) Capital lease obligations are due in various monthly installments up to
$879, including interest up to 19.1% through February 2005, and are
generally collateralized by equipment.
(b) In May 2002, the Company entered into a $220,000 promissory note with
Novartis Consumer Health, Inc. The principal balance of the note was
originally due in December 2003 and was paid off (including accrued interest
of $30,000) in September 2004 out of the licensing fee income proceeds.
Interest was accrued at the prime rate plus 2.0% (effective rate of 6.25%
and 6.0% at July 31, 2004 and December 31, 2003). The promissory note was
collateralized by substantially all of the Company's assets.
NOTE E - COMMITMENTS AND CONTINGENCIES
Leases
The Company conducted its operations in two leased facilities during 2004
and 2003. The corporate building lease expired in February 2005 and the
Company moved operations to the facility in Edina, Minnesota that has a
warehouse lease which expires in August 2008. Both leases provide for
payment of a portion of taxes and other operating expenses by the Company.
The warehouse lease has a provision allowing the Company to terminate the
lease after 36 months (June 30, 2006), provided the Company gives six months
notice and pays a fee of approximately $26,000. It is probable that the
Company will exercise this option if it cannot negotiate a better lease
rate. The Company also leases various equipment under operating leases which
run through June 2005. Total rent expense for operating leases was
$258,043 and $283,671 for 2004 and 2003.
Future minimum lease commitments under operating leases are as follows:
YEAR ENDING DECEMBER 31,
------------------------
2005 $ 82,937
2006 52,677
2007 52,677
2008 35,118
19
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
Employee Benefit Plan
The Company maintains a contributory 401(k) profit sharing benefit plan
covering substantially all employees. The plan allows Company matches of 50%
of employee contributions up to 5% of a participant's compensation. The
Company suspended its matching contributions during 2002. The Company may
also make discretionary contributions. No discretionary contributions were
made for 2004 and 2003.
Legal Proceedings
The Company is subject to various legal proceedings in the normal course of
business. Management believes these proceedings will not have a material
adverse effect on the Company's financial position or results of operations.
NOTE F - INCOME TAXES
Income tax expense (benefit) consists of the following:
YEARS ENDED DECEMBER 31,
------------------------
2004 2003
-------- --------
Current $ 27,000 $ --
Deferred -- --
-------- --------
$ 27,000 $ --
======== ========
20
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
Differences between income tax expense (benefit) and the statutory federal
income tax rate are as follows:
YEARS ENDED DECEMBER 31,
--------------------------
2004 2003
----------- -----------
Federal statutory income tax rate 34.0% (34.0)%
State income taxes, net of federal effect 0.4 --
Change in valuation allowance -- 33.7
Net operating loss carryforward utilized (30.2)
Other (3.0) 0.3
----- -----
1.2% --%
===== =====
Deferred tax assets and liabilities consist of the following:
DECEMBER 31,
--------------------------
2004 2003
----------- -----------
Current assets:
Inventories $ -- $ 101,700
Vacation accrual -- 18,500
Other 56,232 155,100
----------- -----------
Net current assets 56,232 275,300
----------- -----------
Long-term assets (liabilities):
Net operating loss carry-forwards 2,237,412 4,147,500
Tax credit carry-forwards 309,906 295,200
Depreciation -- (37,500)
Charitable contribution carry-forwards -- 5,200
Other -- 20,200
----------- -----------
Net long-term assets 2,547,318 4,430,600
----------- -----------
Net deferred tax assets 2,603,550 4,705,900
Less valuation allowance (2,603,550) (4,705,900)
----------- -----------
Net deferred tax asset $ -- $ --
=========== ===========
At December 31, 2004, the Company has available net operating loss
carry-forwards of approximately $10,400,000 which can be used to reduce
future taxable income. The utilization of a portion of these net operating
loss carry-forwards is restricted under Section 382 of the Internal Revenue
Code due to past ownership changes. These net operating loss carry-forwards
begin to expire in 2008. A valuation allowance has been recorded for these
net operating loss carry-forwards and all other deferred tax assets as they
may not be realizable. The Company continually reviews the adequacy of the
valuation allowance and recognizes those benefits only as the Company's
assessment indicates that it is more likely than not that future tax
benefits will be realized.
21
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
NOTE G - EQUITY TRANSACTIONS
Employee Stock Purchase Plan
The Company had an employee stock purchase plan which expired in November
2003. The plan allowed eligible employees to purchase shares of the
Company's common stock through payroll deductions. The purchase price was
the lower of 85% of the fair market value of the stock on the first or last
day of each six-month period during which an employee participated in the
plan. The Company issued a total of 95,840 shares in connection with
purchases by employees during the life of the plan. The Company issued
12,932 shares for $3,194 during December 31, 2003.
Stock Options and Warrants
The Company has stock option plans for the benefit of selected officers,
employees and directors of the Company. A total of 957,948 shares of common
stock are available for grants of options under the plans at December 31,
2004. Options under the Company's plans are granted at fair market value and
expire at five or ten years from the grant date. Options given to directors
are exercisable at the date of grant. Options given to selected officers and
employees are exercisable at such times as set forth in the individual
option agreements, generally vesting 100% after three to four years.
A summary of the Company's stock option transactions is as follows:
WEIGHTED
NUMBER OF AVERAGE
SHARES EXERCISE PRICE
---------- --------------
Outstanding at December 31, 2002 1,180,142 $ 2.06
Granted 164,000 0.46
Canceled (536,794) (1.08)
---------- ----------
Outstanding at December 31, 2003 807,348 2.39
Granted 75,000 1.20
Exercised (51,003) (0.52)
Canceled (217,221) (2.63)
---------- ----------
Outstanding at December 31, 2004 614,124 $ 2.31
========== ==========
A total of 598,794 and 727,345 options were exercisable at December 31, 2004
and 2003, with a weighted average exercise price of $2.36 and $2.56,
respectively.
On July 1, 2002, 803,958 options outstanding with a weighted average grant
price of $4.54 per share were re-priced to $0.81 per share. At December 31,
2004, 176,000 of these options were exercisable. No compensation expense was
recorded by the Company in connection with the re-pricing, as the exercise
price exceeded the market price on the date of the re-pricing. At December
31, 2004 the exercise price of the re-priced options was below the market
price for the Company's common stock, and the Company recorded compensation
expense of $112,640 for 2004. At December 31, 2003 the exercise price of the
re-priced options equaled the market price for the Company's common stock,
accordingly no compensation expense was recorded in 2003.
22
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2004 AND 2003
The following information applies to grants that are outstanding at December
31, 2004:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------------------------------ ----------------------
WEIGHTED WEIGHTED WEIGHTED
AVERAGE AVERAGE AVERAGE
RANGE OF NUMBER REMAINING EXERCISE NUMBER EXERCISE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE EXERCISABLE PRICE
- --------------- ----------- ---------------- -------- ----------- --------
$ 0.31 - $ 0.35 69,999 0.8 years $ 0.34 54,669 $ 0.35
$ 0.75 - $ 0.81 216,050 0.9 years 0.80 216,050 0.80
$ 1.20 - $ 1.80 97,000 1.3 years 1.32 97,000 1.32
$ 1.90 - $ 2.00 75,000 1.4 years 2.00 75,000 2.00
$ 2.75 - $ 3.63 37,700 0.7 years 2.92 37,700 2.92
$ 5.00 - $ 6.63 80,000 2.5 years 5.85 80,000 5.85
$ 8.38 - $10.00 38,375 0.8 years 9.46 38,375 9.46
------- -------
614,124 $ 2.31 598,794 $ 2.36
======= =======
Stock Repurchase Program
The Company has a stock repurchase program pursuant to which up to 500,000
shares, or approximately 12.0% of the Company's outstanding common stock,
may be repurchased. The shares may be purchased from time to time through
open market transactions, block purchases, tender offers, or in privately
negotiated transactions. The total consideration for all shares repurchased
under this program cannot exceed $2,000,000. There were no shares
repurchased during 2004 and 2003. Since the program's inception, the Company
has repurchased 175,650 shares for $543,400.
Warrants
In connection with the sale of the Company's corporate facility during 2003
(see Note H), the Company issued warrants to an outside party to purchase
200,000 shares of common stock. The warrants are fully exercisable and
entitle the holder to purchase common stock at $0.90 per share until
February 25, 2008. The Company also had outstanding warrants to another
outside party to purchase 12,953 shares of common stock at $6.25 per share,
which expired on November 20, 2004.
NOTE H - SALE OF CORPORATE FACILITY
On February 25, 2003, the Company sold its corporate facility in Minnetonka,
Minnesota for an aggregate purchase price of $910,270 and recorded a loss of
$52,375. In connection with the sale, the Company entered into a lease of
its corporate facility which grants the Company free rent for the 12 months
following the sale/leaseback transaction and thereafter extends the lease at
a rate based on current market conditions. The purchaser also received a
warrant for the purchase of 200,000 shares of common stock at $0.90 per
share.
NOTE I - SUBSEQUENT EVENT
On January 20, 2005, the Company's Board of Directors approved and declared
a cash dividend of $0.06 per share, payable on March 11, 2005 to
shareholders of record on February 25, 2005. The Company had 4,113,739
shares outstanding on the record date.
23
PART III
ITEM 13. EXHIBITS
Method of
Filing
---------
3.01 Articles of Incorporation of LecTec Corporation, as amended (1)
3.02 Bylaws of LecTec Corporation (1)
10.01 Certificate of Secretary pertaining to Resolution of Board of
Directors of LecTec Corporation, dated October 30, 1986,
implementing a Profit Sharing Bonus Plan (1)
**10.02 LecTec Corporation 1989 Stock Option Plan (2)
**10.03 LecTec Corporation 1991 Directors' Stock Option Plan (2)
10.04 Change In Control Termination Pay Plan adopted May 27, 1998 (3)
**10.05 LecTec Corporation Employee Stock Purchase Plan (4)
**10.06 LecTec Corporation 1998 Stock Option Plan (5)
**10.07 LecTec Corporation 1998 Directors' Stock Option Plan (5)
**10.08 LecTec Corporation 2001 Stock Option Plan (6)
10.09 Sale Leaseback Agreement By and Between LecTec Corporation and
Larry Hopfenspirger, dated February 25, 2003. (7)
24
Exhibit Method of
No. Filing
------- ---------
10.10 Office/warehouse lease dated May 23, 2003, by and between SMD
Lincoln Investments LLC and LecTec Corporation. (8)
*10.11 Supply and License Agreement By and Between LecTec Corporation and
Novartis Consumer Health, Inc. executed on July 19, 2004 and effective (9)
as of January 1, 2004.
10.12 Promissory Note By and Between LecTec Corporation and Novartis
Consumer Health, Inc. executed on July 19, 2004 and effective as of (9)
January 1, 2004.
10.13 Security Agreement By and Between LecTec Corporation and Novartis
Consumer Health, Inc. executed on July 19, 2004 and effective as of (9)
January 1, 2004.
10.14 General Terms and Conditions for the Purchase of Capital Equipment
dated as of December 2, 2004 between Novartis Consumer Health, Inc. (10)
and LecTec Corporation.
10.15 Separation Agreement dated December 28, 2004 by and between LecTec
Corporation and Timothy P. Fitzgerald. (11)
23.01 Consent of Lurie Besikof Lapidus & Company, LLP (12)
23.02 Consent of Grant Thornton LLP (12)
24.01 Power of Attorney (11)
31.01 Certification of Principal Executive Officer (12)
31.02 Certification of Principal Financial Officer (12)
32.01 Chief Executive Officer Certification Pursuant to 18 U.S.C. 1350, as
adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002. (12)
99.01 Cautionary Statements (11)
25
Notes to Exhibits - Method of Filing
* Confidential treatment has been granted for portions of this Exhibit
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as
amended. The confidential portions have been deleted and filed
separately with the United States Securities and Exchange Commission.
** Management contract or compensatory plan or arrangement required to be
filed as an exhibit to this Form 10-KSB.
(1) Incorporated herein by reference to the Company's Form S-18
Registration Statement (file number 33-9774C) filed on October 31,
1986 and amended on December 12, 1986.
(2) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended June 30, 1997.
(3) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended June 30, 1998.
(4) Incorporated herein by reference to the Company's Registration
Statement on Form S-8 (file number 333-72571) filed on February 18,
1999.
(5) Incorporated herein by reference to the Company's Registration
Statement on Form S-8 (file number 333-72569) filed on February 18,
1999.
(6) Incorporated herein by reference to the Company's Registration
Statement on Form S-8 (file number 333-68920) filed on September 4,
2001.
(7) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended December 31, 2002.
(8) Incorporated herein by reference to the Company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 2003.
(9) Incorporated herein by reference to the Company's Quarterly Report on
Form 10-QSB for the quarter ended June 30, 2004.
(10) Incorporated herein by reference to the Company's Current Report on
Form 8-K filed on December 30, 2004.
(11) Previously filed with the original Form 10-KSB for the fiscal year
ended December 31, 2004.
(12) Filed herewith.
26
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
has caused this amendment to be signed on its behalf by the undersigned,
thereunto duly authorized, on the 11th day of November, 2005.
LECTEC CORPORATION
/s/ Alan C. Hymes, M.D.
-----------------------
Alan C. Hymes, M.D.
Chief Executive Officer
27
EXHIBIT INDEX
Exhibit No.
- -----------
3.01 Articles of Incorporation of Registrant, as amended (Note 1).
3.02 Bylaws of Registrant (Note 1).
10.01 Certificate of Secretary pertaining to Resolution of Board of
Directors of LecTec Corporation, dated October 30, 1986,
implementing a Profit Sharing Bonus Plan (Note 1).
** 10.02 LecTec Corporation 1989 Stock Option Plan (Note 2).
** 10.03 LecTec Corporation 1991 Directors' Stock Option Plan (Note 2).
** 10.04 Change In Control Termination Pay Plan adopted May 27, 1998 (Note 3).
** 10.05 LecTec Corporation Employee Stock Purchase Plan (Note 4).
** 10.06 LecTec Corporation 1998 Stock Option Plan (Note 5).
** 10.07 LecTec Corporation 1998 Directors' Stock Option Plan (Note 5).
** 10.08 LecTec Corporation 2001 Stock Option Plan (Note 6).
10.09 Sale Leaseback Agreement By and Between LecTec Corporation and
Larry Hopfenspirger, dated February 25, 2003 (Note 7).
10.10 Office/warehouse lease May 23, 2003, by and between SMD Lincoln
Investments LLC and LecTec Corporation (Note 8).
*10.11 Supply and License Agreement By and Between LecTec Corporation
and Novartis Consumer Health, Inc. executed on July 19, 2004 and
effective as of January 1, 2004 (Note 9).
10.12 Promissory Note By and Between LecTec Corporation and Novartis
Consumer Health, Inc. executed on July 19, 2004 and effective as
of January 1, 2004 (Note 9).
10.13 Security Agreement By and Between LecTec Corporation and Novartis
Consumer Health, Inc. executed on July 19, 2004 and effective as
of January 1, 2004 (Note 9).
10.14 General Terms and Conditions for the Purchase of Capital
Equipment dated as of December 2, 2004 between Novartis Consumer
Health, Inc. and LecTec Corporation (Note 10).
10.15 Separation Agreement dated December 28, 2004 by and between
LecTec Corporation and Timothy P. Fitzgerald (Note 11).
23.01 Consent of Lurie Besikof Lapidus & Company, LLP (Note 12).
23.02 Consent of Grant Thornton LLP (Note 12).
24.01 Power of Attorney (Note 11).
31.01 Certification of Principal Executive Officer (Note 12).
31.02 Certification of Principal Financial Officer (Note 12).
32.01 Chief Executive Officer Certification Pursuant to 18 U.S.C.1350,
as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
2002 (Note 12).
99.01 Cautionary Statements (Note 11).
28
Exhibit Notes:
* Confidential treatment has been granted for portions of this Exhibit
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as
amended. The confidential portions have been deleted and filed separately
with the United States Securities and Exchange Commission.
** Management contract or compensatory plan or arrangement required to be
filed as an exhibit to this Form 10-KSB.
(1) Incorporated herein by reference to the Company's Form S-18 Registration
Statement (file number 33-9774C) filed on October 31, 1986 and amended on
December 12, 1986.
(2) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended June 30, 1997.
(3) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended June 30, 1998.
(4) Incorporated herein by reference to the Company's Registration Statement
on Form S-8 (file number 333-72571) filed on February 18, 1999.
(5) Incorporated herein by reference to the Company's Registration Statement
on Form S-8 (file number 333-72569) filed on February 18, 1999.
(6) Incorporated herein by reference to the Company's Registration Statement
on Form S-8 (file number 333-68920) filed on September 4, 2001.
(7) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended December 31, 2002.
(8) Incorporated herein by reference to the Company's Quarterly Report on Form
10-QSB for the quarter ended June 30, 2003.
(9) Incorporated herein by reference to the Company's Quarterly Report on Form
10-QSB for the quarter ended June 30, 2004.
(10) Incorporated herein by reference to the Company's Current Report on Form
8-K filed on December 30, 2004.
(11) Previously filed with the original Form 10-KSB for the fiscal year ended
December 31, 2004.
(12) Filed herewith.
29